Understanding how kidney tumors in Tuberous Sclerosis Complex resist treatment to create new therapies
Elucidation of Tumor Resistance Mechanisms in Tuberous Sclerosis Complex-Associated Renal Angiomyolipoma for the Design of Novel Nanotherapies
This study is looking at how certain kidney tumors in people with Tuberous Sclerosis Complex resist treatment, so researchers can learn more about them and find better ways to help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11093992 on NIH RePORTER |
What this research studies
This research focuses on patients with Tuberous Sclerosis Complex (TSC) who develop benign kidney tumors called renal angiomyolipomas (AML). The study aims to uncover the mechanisms behind the tumors' resistance to current treatments, particularly the drug everolimus, which only partially reduces tumor size. By using genetically engineered patient-derived stem cells to create organoids that mimic these tumors, researchers hope to better understand their biology and develop more effective therapies. This innovative approach could lead to breakthroughs in treating AML and improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Tuberous Sclerosis Complex who have developed renal angiomyolipomas.
Not a fit: Patients without Tuberous Sclerosis Complex or those who do not have renal angiomyolomas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for kidney tumors in Tuberous Sclerosis Complex patients.
How similar studies have performed: While there have been challenges in studying renal angiomyolipomas, this approach using patient-derived organoids is novel and has not been extensively tested in this context.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Lemos, Dario — Brigham and Women's Hospital
- Study coordinator: Lemos, Dario
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.